Brought to you by 
Alcon, Dharmacon develop RNAi-based ophthalmic therapeutics
05 Dec 2005
Executive Summary
Nestle SA's eye care company Alcon, through its Alcon Research and Alcon Manufacturing units, will work with Fisher Scientific subsidiary Dharmacon (RNA technologies) to develop ophthalmic therapeutics based on RNAi.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alcon, Dharmacon develop RNAi-based ophthalmic therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice